{"organizations": [], "uuid": "1b220f3feb2fb84563ebf149caf16359dc58bc45", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-therapeuticsmd-enters-into-negotia/brief-therapeuticsmd-enters-into-negotiations-with-u-s-fda-for-tx-004hr-idUSFWN1RO0FS", "country": "US", "domain_rank": 408, "title": "BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-11T13:31:00.000+03:00", "replies_count": 0, "uuid": "1b220f3feb2fb84563ebf149caf16359dc58bc45"}, "author": "", "url": "https://www.reuters.com/article/brief-therapeuticsmd-enters-into-negotia/brief-therapeuticsmd-enters-into-negotiations-with-u-s-fda-for-tx-004hr-idUSFWN1RO0FS", "ord_in_thread": 0, "title": "BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR Reuters Staff \n  TherapeuticsMD Inc: \n* ENTERS INTO LABEL NEGOTIATIONS FOR TX-004HR \n* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR \n* DOES NOT ANTICIPATE PROVIDING SUBSEQUENT UPDATES WITH RESPECT TO LABEL NEGOTIATIONS PRIOR TO PDUFA TARGET ACTION DATE \n* PDUFA TARGET ACTION DATE FOR COMPLETION OF FDAâ€™S REVIEW OF NEW DRUG APPLICATION (NDA) FOR TX-004HR IS MAY 29, 2018 Source text for Eikon:  ", "external_links": [], "published": "2018-04-11T13:31:00.000+03:00", "crawled": "2018-04-11T13:52:51.002+03:00", "highlightTitle": ""}